Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • Bitcoin CAD

    83,238.67
    -2,749.49 (-3.20%)
     
  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     

What Endo International’s Valuation Trend Indicates

What Endo International’s Valuation Trend Indicates

Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.